Connect Biopharma Holdings Limited CNTB
At closeNov 6, 2026, 7:51 PM EST
After hours · Nov 6, 7:51 PM ET
- YTD
- -74.16%
- 1 year
- -56.10%
- Market cap
- 45.89M
- Revenue (ttm)
- 24.12M
- Profit margin
- -88.66%
- EPS (ttm)
- -1.19
- Shares out
- 55.25M
- Forward P/E
- -5.04
- YTD return
- -74.16%
- 1-year return
- -56.10%
- Volume
- 338.79K
- Avg volume
- 3.99M
- Open
- 0.7532
- Previous close
- 0.7317
- Day's range
- 0.71 – 0.7615
- 52-week range
- 0.7287 – 3.69
- Beta
- -0.31
- Price target
- 7.00 (+860.6%)
- Earnings date
- Mar 30, 2023
5D -0.0640 (-8.10%)
Key statistics
- Enterprise value
- -57.37M
- PEG ratio
- 0.00
- Price / sales
- 2.31
- Price / book
- 0.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -17.08M
- Total cash
- 110.24M
- Total debt
- 325.00K
- Return on equity
- -17.92%
- Short % of float
- 0.18%
- 50-day average
- 1.12
- 200-day average
- 1.34
Analyst view
- Target (low)
- 6.00
- Target (mean)
- 7.00
- Target (high)
- 8.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 30, 2023
Expected Mar 30, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 30, 2023 | Dec 1, 2022 | -0.48 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 17, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 4, 2024 | HC Wainwright & Co. | init | — | Buy |
| Sep 13, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Feb 8, 2023 | SVB Leerink | main | — | Outperform |
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- connectbiopharm.com
News
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target - Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4
- HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views 
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5 
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
Your note
Sign in to keep a note on CNTB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 3.79% | 2,093,232 | 2.11M | Sep 29, 2024 |
| O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 0.92% | 510,701 | 514.48K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.32% | 175,500 | 176.80K | Sep 29, 2024 |
| Callan Capital LLC | 0.08% | 41,823 | 42.13K | Sep 29, 2024 |
| Keudell/Morrison Wealth Management | 0.06% | 33,450 | 33.70K | Sep 29, 2024 |
| Royal Bank of Canada | 0.06% | 30,600 | 30.83K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 27,961 | 28.17K | Oct 30, 2024 |